Keros Therapeutics (KROS) Misses Q1 EPS by 18c

Keros Therapeutics (NASDAQ: KROS) reported Q1 EPS of ($1.21), $0.18 worse than the analyst estimate of ($1.03). Revenue for the quarter came in at $370 thousand versus the consensus estimate of $1.69 million.

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
• Fed’s Musalem says more rate hikes likely needed to curb inflation
• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar